Using the science of ARS to transform the next generation of drug discovery

At ZYMEDI we are putting our extensive knowledge of aminoacyl-tRNA synthetase (ARS) science to work to transform the next generation of drug discovery.

Focused on the most challenging inflammatory diseases and various refractory cancers, our pipeline has unlimited potential. It includes first-in-class treatments for pulmonary arterial hypertension (PAH), nonalcoholic steatohepatitis (NASH), and a pan-KRAS inhibitor that targets AIMP2-DX2 for KRAS-mutated cancers followed by additional target and lead platforms.

The ZYMEDI pipeline

ZYMEDI pipeline
ZYMEDI is developing the first-in-class medication to treat PAH at its source.
Our first-in-class treatment inhibits multiple proinflammatory activities of KARS1 in extracellular space.
ZYMEDI is developing a pan-KRAS inhibitor cancers, including colon, lung, and pancreatic.

Contact ZYMEDI

We welcome joint ventures, strategic investors, and in-licensing partners who want to be part of our mission to identify novel therapeutics for hard-to-treat disease areas. To learn more, or to partner with ZYMEDI, contact us today.